By John Revill
ZURICH (Reuters) -Roche Chief Government Thomas Schinecker and different senior executives from the Swiss prescribed drugs trade will meet with the federal government on Monday to debate the risk U.S. tariffs pose to the essential export sector.
Washington has imposed a 39% tariff – among the many steepest of any nation focused throughout President Donald Trump‘s world commerce reset – on items akin to watches and equipment imported from Switzerland. Swiss prescribed drugs are at present not topic to that levy.
The pharma trade is, in the meantime, additionally awaiting the end result of a Part 232 nationwide safety investigation that might end in tariffs on U.S. drug imports finally reaching 250%.
PHARMACEUTICALS: MOST IMPORTANT SWISS EXPORT
Along with Roche, Novartis and Sandoz can even ship executives to the assembly in Bern with Enterprise Minister Man Parmelin and Well being Minister Elisabeth Baume-Schneider, the federal government mentioned.
Roche, Novartis and Sandoz didn’t instantly reply to requests for remark.
Different anticipated contributors embody representatives from Merck, Johnson & Johnson, and Australian biotech agency CSL, the federal government mentioned.
Parmelin, who travelled to Washington earlier this month, has been main the Swiss response to Trump’s tariffs, although the present tariff negotiations won’t be mentioned on the assembly, a authorities spokesperson mentioned.
Different matters may embody drug costs in Switzerland, which the well being ministry agrees with firms.
Prescribed drugs are by far an important Swiss export sector to the USA, with shipments value 32.75 billion Swiss francs ($41.28 billion), making up about half of Swiss exports there final 12 months.
If the 39% tariff is prolonged to cowl prescribed drugs, Swiss financial output may fall by greater than 1%, in line with one estimate.
Swiss pharma exports to the U.S. have fallen since April after importers stockpiled earlier this 12 months to keep away from having to pay any levies.
Swiss firms, together with pharma companies, have already pledged to extend their spending in the USA to cut back the influence of import duties.
Roche has unveiled plans to speculate $50 billion over the following 5 years within the U.S., creating greater than 12,000 new jobs, whereas Novartis has mentioned it plans to spend $23 billion to construct and increase 10 services there.
Novartis desires to make most necessary merchandise for the American market domestically, CEO Vas Narasimhan mentioned in an interview revealed on Saturday.
“This could enable us to completely mitigate any tariffs,” he mentioned.
($1 = 0.7933 Swiss francs)
(Reporting by John Revill; Modifying by Joe Bavier)
